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Acute heart failure (AHF) is the most common diagnosis in the emergency department (ED) 
leading to hospitalization.1,2 In contrast to the enormous improvements achieved in the 
management of patients with chronic heart failure, morbidity and mortality remain 
unacceptably high in patients with AHF.1–3 The dismal outcome of patients with AHF may at 
least in part be related to diagnostic uncertainty in the ED and the associated delay in diagnosis 
and initiation of effective treatment.3 
The clinical introduction of natriuretic peptides as quantitative markers of 
hemodynamic stress and heart failure provided a novel and unique non-invasive window to the 
heart and has substantially improved the rapid detection of AHF among patients presenting 
with acute dyspnea.1–3 Accordingly, the diagnostic use of natriuretic peptides has received a 
class I recommendation in both the European and the American practice guidelines.1,2 While 
the cut-off concentrations of B-type natriuretic peptide (BNP) recommended in current 
guidelines were validated in a large, multicentre study,4 only recently, the performance of the 
NT-proBNP cut-off concentrations has been tested in a North American and an Asian cohort 
of relatively young patients with low prevalence of AHF and less comorbidities as compared 
to that observed in European patients.2,5–7 We therefore aimed to address this major gap in 
knowledge and prospectively validate NT-proBNP cut-off concentrations in the diagnosis of 
AHF in the European multicentre cohort Basics in Acute Shortness of Breath EvaLuation 
(BASEL V) (NCT01831115).  
We enrolled unselected adult patients presenting to the ED of two Swiss University 
Hospitals (Basel and Zurich) with acute dyspnea as their chief complaint. While enrolment was 
independent of renal function, patients with terminal kidney failure on chronic dialysis were 
excluded. For this analysis, patients were also excluded if they did not have NT-proBNP 
plasma concentrations measured from study blood samples at ED presentation, if the final 
diagnosis remained unclear even after central adjudication, and if the patients were adjudicated 
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to have cardiac dyspnea due to acute coronary syndrome or arrhythmia without any other 
evidence for AHF. Two independent cardiologists/internists centrally adjudicated the final 
diagnosis using all individual patient's information including chest x-ray, natriuretic peptide, 
renal dysfunction (defined as estimated glomerular filtration rate <60 mL/min/1.73m² at 
presentation), echocardiography, pulmonary function test, and 90-day follow-up, in 
consistence with current guidelines.1,2 Accordingly, in 1,633 (80%) patients the adjudication 
was performed blinded to NT-proBNP concentrations, in 420 (20%) patients NT-proBNP 
concentrations were part of extensive dataset available for the adjudication. In situations of 
disagreement about the diagnosis, cases were reviewed and adjudicated in conjunction with a 
third cardiologist. The study was carried out according to the principles of the Declaration of 
Helsinki and approved by the local ethics committees. All patients provided a written informed 
consent.  
 Specificity, positive predictive value (PPV), and the percentage of patients triaged 
towards rule-in were the primary outcome measures for the age-dependent NT-proBNP rule-
in cut-off concentrations (450 pg/mL if <50 years, 900 pg/mL if 50-75 years, and 1,800 pg/mL 
if >75 years).1,2,5–7 Sensitivity, negative predictive value (NPV), and the percentage of patients 
triaged towards rule-out were the primary outcome measures for the universal NT-proBNP 
rule-out cut-off concentration (300 pg/mL).1,2,5–7 The relevant 95% confidence intervals (CIs) 
were defined by using the Wilson score method without continuity correction. Diagnostic 
accuracy of NT-proBNP plasma concentrations to diagnose AHF was quantified by using the 
area under the receiver operating characteristic curves (AUC). Comparison of AUC was 
performed as recommended by DeLong.  
Among 2,053 patients eligible for analysis, 1,043 patients (51%) had an adjudicated 
diagnosis of AHF. For the rapid rule-in of AHF, the currently recommended age-dependent 
cut-off concentrations of NT-proBNP (450 pg/mL if <50 years old, 900 pg/mL if 50-75 years 
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old, and 1,800 pg/mL if >75 years old) achieved a specificity of 91% (95% CI, 87-95%), 84% 
(95% CI, 81-87%), and 81% (95% CI, 76-85%), a positive predictive value of 60% (95% CI, 
45-73%), 79% (95% CI, 74-82%), and 90% (95% CI, 88-92%), allowing to rule-in AHF in 
19%, 45%, and 62% of patients, respectively. For the rapid rule-out of AHF, the universal cut-
off of 300 pg/mL achieved a sensitivity of 98% (95% CI, 97-99%), a negative predictive value 
of 97% (95% CI, 95-98%), and allowed to rule-out AHF in 29% of patients (Figure and Table). 
Compared to the clinical judgment in ED alone, its combination with NT-proBNP plasma 
concentrations showed significantly higher diagnostic accuracy as quantified by using the AUC 
(0.889 [95% CI, 0.863-0.915] vs. 0.935 [95% CI, 0.915-0.954], p<0.001). 
Sensitivity analysis excluding the subgroup of patients in which among multiple other 
clinical variables also NT-proBNP plasma concentrations were available for the final 
adjudication revealed similar findings. Further separating the age-strata into patients with 
normal renal function versus renal dysfunction showed that the presence of renal dysfunction 
increased NT-proBNP plasma concentrations, reduced the specificity for AHF, while it tended 
to increase the sensitivity at the currently recommended NT-proBNP cut-off concentrations. 
 These findings extend and corroborate previous work on the best possible clinical use 
of natriuretic peptides in the early diagnosis of AHF.1–3,5–7 First, natriuretic peptides should 
be interpreted as quantitative markers of hemodynamic cardiac stress and heart failure. Low 
concentrations provide a very high NPV for AHF and allow triaging patients towards rule-
out. For patients presenting with acute dyspnea in the ED, concentrations below 300ng/L for 
NT-proBNP and below 100ng/L for BNP balance the safety and efficacy of rule-out well. 
High concentrations provide a high PPV for AHF and allow triaging patients towards rule-in. 
6–8 Second, while patients with BNP or NT-proBNP plasma concentration in the ‘grey zone’ 
have a broad differential diagnosis and usually require full clinical work-up, most of them 
will finally be found to have mild heart failure.8 Third, even in the presence of renal 
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dysfunction the utility of NT-proBNP in the rapid triage of dyspneic patients in the ED 
remains high.5,6 
In conclusion, this large two-centre diagnostic study using central adjudication 
confirmed that currently recommended NT-proBNP cut-off concentrations perform well in the 
rapid diagnosis of AHF in elderly European patients with acute dyspnea in the ED.  
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Figure legend 
Figure. NT-proBNP based diagnosis of AHF across the predefined age groups.  
For AHF rapid rule-in, currently recommended NT-proBNP cut-off concentrations (450 
pg/mL if <50, 900 pg/mL if 50-75, and 1,800 pg/mL if >75) achieved specificity of 91%, 
84%, and 81%. For rapid rule-out, the universal cut-off concentration of 300 pg/mL achieved 
sensitivity of 98%. 
AHF denotes acute heart failure; AUC denotes area under the curve; NT-proBNP denotes N-
terminal pro-B-type natriuretic peptide; ROC denotes receiver operating characteristic. 
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Table. Optimal NT-proBNP cut-off concentrations for the diagnosis or exclusion of AHF among patients with acute dyspnea 
Category Recommended 
cut-off 
concentration 
Sensitivity, % 
(95% CI*) 
Specificity, % 
(95% CI) 
PPV, % 
(95% CI) 
NPV, % 
(95% CI) 
Accuracy, % 
(95% CI) 
Confirmatory 
(‘rule-in’) cut-off 
concentrations 
      
Rule-in, overall 
 
 84 
(81-86) 
84 
(82-87) 
85 
(82-87) 
83 
(81-85) 
84 
(82-86) 
   <50 years old     
(n=224) 
450 pg/mL 89 
(73-96) 
91 
(87-95) 
60 
(45-73) 
98 
(95-99) 
91 
(87-94) 
   50–75 years old 
(n=842) 
900 pg/mL 88 
(85-91) 
84 
(81-87) 
79 
(74-82) 
92 
(89-94) 
86 
(83-88) 
   >75 years old     
(n=987) 
1,800 pg/mL 81 
(78-84) 
81 
(76-85) 
90 
(88-92) 
66 
(61-70) 
81 
(78-83) 
Exclusionary 
(‘rule-out’) cut-
off concentration 
      
   All patients     
(n=2053) 
300 pg/mL 
 
98 
(97-99) 
57 
(54-60) 
70 
(68-72) 
97 
(95-98) 
78 
(76-79) 
* The method used to calculate the confidence interval for a proportion is the Wilson score method without continuity correction. 
AHF = acute heart failure; NPV = negative predictive value; NT-proBNP = N-terminal pro-B-type natriuretic peptide; PPV = positive predictive value; CI = 
confidence interval 
